NCT02685306撤回2 期
A Phase II Study to Determine the Pathological Complete Response Rate and Immunomodulatory Effects of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
Peregrine Pharmaceuticals0 个研究点开始时间: 2016年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 主要终点
- Pathological Complete Response (pCR) rate of neoadjuvant paclitaxel in combination with bavituximab in patients with early- stage triple- negative breast cancer (TNBC)
研究概览
简要总结
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug taxane, will improve the results of the treatment for early- stage Triple Negative Breast Cancer followed by Standard- of- Care surgery
详细描述
This is an open-label randomized trial in patients with early- stage Triple Negative Breast Cancer. Patients will be treated with either paciltaxel alone or paclitaxel with bavituximab. Paclitaxel will be given weekly, and bavituximab will be given weekly. All therapy will continue for up to twelve doses of treatment followed by standard of care definitive surgical resection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent has been obtained prior to screening.
- •Target Population
- •Female or male at least 18 years of age.
- •Invasive breast cancer confirmed by pathology evaluation of core biopsy.
- •Early-stage TNBC according to the American Joint Committee on Cancer (AJCC) Staging Manual Clinical Stage I (T1c, > 1.5 cm), Stage II or Stage III invasive breast cancer.
- •Tumors must be ER/PgR status negative (IHC < 1%) and lack of HER2/neu overexpression or amplification as measured by local hospital pathology laboratory (IHC +/- fluorescence in situ hybridization (FISH) and IHC < 3+, and FISH < 2.2) as described in the NCCN Guidelines.
- •Patient must consent to a minimum of 1 tumor-containing formalin fixed paraffin embedded core (or archival tissue) or baseline research biopsy.
- •Eastern Cooperative Oncology Group Performance Status 0 or
- •Adequate hematologic function (absolute neutrophil count ≥ 1,500 cells/µL; hemoglobin > 9 g/dL, platelets > 100,000/µL.).
- •Adequate renal function (serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance ≥ 60 mL/min using Cockcroft-Gault equation).
- •Adequate hepatic function: total bilirubin ≤ upper limit of normal (ULN), serum albumin ≥≥ 3.0 g/dL, alanine aminotransferase and aspartate aminotransferase ≤ 1.5 x ULN.
- •Prothrombin time and/or international normalized ratio (INR) ≤ 1.5 x ULN and activated partial thromboplastin time ≤ 1.5 x ULN, if patient is not on anticoagulant therapy.
- •Female patients must have a negative serum human chorionic gonadotropin test within 1 week of Day 1 (pregnancy test not required for patients with bilateral oophorectomy and/or hysterectomy or for those patients who are > 1 year postmenopausal
- •Women of childbearing potential must avoid becoming pregnant and men must avoid fathering a child during and for 3 months after the end of study treatment.
排除标准
- •Surgically unresectable, inflammatory, or metastatic breast cancer.
- •Any prior treatment for current breast cancer including chemotherapy, hormonal therapy, radiation, or other experimental therapy.
- •Known history of bleeding diathesis or coagulopathy (e.g., von Willebrand disease or hemophilia).
- •Clinically significant bleeding, such as gross hematuria, gastrointestinal bleeding before screening (if clinically significant bleeding has occurred within 6 months of screening, but the cause has been identified and adequately treated [e.g., cystitis, ulcer], then this exclusion criterion does not apply. Minor biopsy-related bleeding lasting < 24 hours and resolved at least 1 week before Day 1 is allowed.
- •Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or arterial thrombosis) occurring within 6 months before screening.
- •Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease, active infections).
- •Autoimmune disease requiring treatment with chronic systemic immunosuppressive therapy. Prior allotransplantation.
- •History of hypersensitivity to any of the excipients of paclitaxel (e.g., Cremaphor).
- •Has an active infection requiring systemic therapy.
- •Major surgery within 4 weeks prior to Day 1
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- •Investigational therapy within 28 days prior to Day
- •Is pregnant or breastfeeding, or expecting to conceive within the projected duration of the trial.
- •Has a known history of human immunodeficiency virus (HIV) (HIV1/2 antibodies) or active hepatitis B (e.g., HBsAg reactive) or hepatitis C (e.g., hepatitis C virus RNA [qualitative] is detected.
研究组 & 干预措施
Taxane
Active Comparator
Taxane (Paclitaxel) weekly on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
干预措施: Taxane (Drug)
Bavituximab plus Taxane
Experimental
Bavituximab 3 mg/kg weekly PLUS Taxane (Paclitaxel) on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
干预措施: Bavituximab (Biological)
Bavituximab plus Taxane
Experimental
Bavituximab 3 mg/kg weekly PLUS Taxane (Paclitaxel) on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
干预措施: Taxane (Drug)
结局指标
主要结局
Pathological Complete Response (pCR) rate of neoadjuvant paclitaxel in combination with bavituximab in patients with early- stage triple- negative breast cancer (TNBC)
时间窗: Approximately 24 months
次要结局
- Safety Measures - Adverse Events and Laboratory Evaluations(approximately 24 months)
研究者
相似试验
撤回
2 期
Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast CancerMetastatic Breast CancerNCT02651610Peregrine Pharmaceuticals
已完成
2 期
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung CancerNon-small-cell Lung CancerNCT01138163Peregrine Pharmaceuticals121
已完成
3 期
Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung CancerNon-Small-Cell Lung Cancer Stage IIIBNon-Small-Cell Lung Cancer Stage IVNon-Small-Cell Lung Cancer MetastaticCarcinoma, Non-Small-Cell LungNon-Small-Cell Lung CarcinomaNonsmall Cell Lung CancerNon-Small Cell Lung CancerNCT01999673Peregrine Pharmaceuticals582
已完成
2 期
A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast CancerBreast CancerNCT00669591Peregrine Pharmaceuticals46
撤回
2 期
Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung CancerNon-Small Cell Lung CancerNCT02673814Peregrine Pharmaceuticals